ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

on: May 21, 2025In: Evolving Standards of Care
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education. Read more

The Peaks and Valleys in Lung Cancer Therapeutics Research

on: May 27, 2019In: Evolving Standards of Care
The Peaks and Valleys in Lung Cancer Therapeutics Research

By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances […] Read more

What Can We Offer a Patient with a Malignant Mesothelioma?

on: May 26, 2019In: Evolving Standards of Care
What Can We Offer a Patient with a Malignant Mesothelioma?

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to […] Read more

2019 IASLC Best of the World Lung Cancer Conference Results in New Virtual Collaboration

on: May 26, 2019In: Evolving Standards of Care
2019 IASLC Best of the World Lung Cancer Conference Results in New Virtual Collaboration

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […] Read more

Checkpoint Inhibitors and Clinical Decision Making: A Q&A with Dr. Nasser H. Hanna

on: May 26, 2019In: Evolving Standards of Care
Checkpoint Inhibitors and Clinical Decision Making: A Q&A with Dr. Nasser H. Hanna

Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes […] Read more

Lorlatinib’s Role in ROS1-Positive Lung Cancer

on: May 26, 2019In: Evolving Standards of Care
Lorlatinib’s Role in ROS1-Positive Lung Cancer

By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. […] Read more

ICU Care for the Patient with Lung Cancer

on: April 04, 2019In: Evolving Standards of Care
ICU Care for the Patient with Lung Cancer

By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […] Read more

Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC

on: April 04, 2019In: Evolving Standards of Care
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC

Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have […] Read more

Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

on: April 04, 2019In: Evolving Standards of Care
Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it […] Read more

Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

on: February 26, 2019In: Evolving Standards of Care
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019  Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […] Read more

The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management

on: November 08, 2018In: Evolving Standards of Care
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management

By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease […] Read more

«‹22232425262728›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy